Cracking the estrogen receptor's posttranslational code in breast tumors

Endocrine Reviews

Volumn 32, Issue 5, 2011, Pages 597-622

  Le Romancer, Muriel ^a,b,c,d,e   Poulard, Coralie ^a,b,c,d,e   Cohen, Pascale ^a,b,c,d,e   Sentis, Stéphanie ^a,b,c,d,e   Renoir, Jack Michel ^f,g   Corbo, Laura ^a,b,c,d,e  

^a UNIVERSITÉ DE LYON   (France)

^b UNIVERSITÉ LYON 1   (France)

^c INSERM   (France)

^d CNRS   (France)

^e CENTRE LÉON BÉRARD   (France)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; ANASTROZOLE; ARGININE; CYCLIN D1; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; EXEMESTANE; FULVESTRANT; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE 6; LETROZOLE; METHYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P21; RALOXIFENE; TAMOXIFEN; TUBULIN;

ACETYLATION; BREAST CANCER; CANCER GROWTH; CANCER HORMONE THERAPY; CARCINOGENESIS; CELL SURVIVAL; DEACETYLATION; DNA BINDING; DRUG RESISTANCE; ESTROGEN RESPONSIVE ELEMENT; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC CODE; GLYCOSYLATION; HORMONE RESPONSE; HUMAN; LIGAND BINDING; METHYLATION; NONHUMAN; PALMITOYLATION; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN STABILITY; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; SUMOYLATION; UBIQUITINATION;

ACETYLATION; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR MODULATORS; ESTROGENS; FEMALE; HUMANS; METHYLATION; MUTATION; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; UBIQUITINATION;

EID: 81255186483     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/er.2010-0016     Document Type: Review

References (273)

1. Couse JF, Korach KS 1999 Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev 20:358-417
2. Santen RJ, Boyd NF, Chlebowski RT, Cummings S, Cuzick J, Dowsett M, Easton D, Forbes JF, Key T, Hankinson SE, Howell A, Ingle J 2007 Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. Endocr Relat Cancer 14:169-187
3. McDonnell DP, Norris JD 2002 Connections and regulation of the human estrogen receptor. Science 296:1642-1644
4. Levin ER 2009 Membrane oestrogen receptor α signalling to cell functions. J Physiol 587:5019-5023
5. Russo J, Ao X, Grill C, Russo IH 1999 Pattern of distribution of cells positive for estrogen receptor α and progesterone receptor in relation to proliferating cells in the mammary gland. Breast Cancer Res Treat 53:217-227
6. Pettersson K, Delaunay F, Gustafsson JA 2000 Estrogen receptor β acts as a dominant regulator of estrogen signaling. Oncogene 19:4970-4978
7. Ström A, Hartman J, Foster JS, Kietz S, Wimalasena J, Gustafsson JA 2004 Estrogen receptor β inhibits 17β-estradiol- stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci USA 101:1566-1571
8. Treeck O, Lattrich C, Springwald A, Ortmann O 2010 Estrogen receptorβ exerts growth-inhibitory effects on human mammary epithelial cells. Breast Cancer Res Treat 120:557-565
9. Behrens D, Gill JH, Fichtner I 2007 Loss of tumourigenicity of stably ERβ-transfected MCF-7 breast cancer cells. Mol Cell Endocrinol 274:19-29
10. Lazennec G, Bresson D, Lucas A, Chauveau C, Vignon F 2001 ER β inhibits proliferation and invasion of breast cancer cells. Endocrinology 142:4120-4130
11. Williams C, Edvardsson K, Lewandowski SA, Ström A, Gustafsson JA 2008 Agenome-wide study of the repressive effects of estrogen receptor β on estrogen receptor α signaling in breast cancer cells. Oncogene 27:1019-1032
12. Colditz GA 1998 Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J Natl Cancer Inst 90:814-823
13. Crandall DL, Busler DE, Novak TJ, Weber RV, Kral JG 1998 Identification of estrogen receptor β RNA in human breast and abdominal subcutaneous adipose tissue. Biochem Biophys Res Commun 248:523-526
14. Harvey JM, Clark GM, Osborne CK, Allred DC 1999 Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474-1481
15. Ali S, Coombes RC 2002 Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2:101-112
16. Taylor SE, Martin-Hirsch PL, Martin FL 2010 Oestrogen receptor splice variants in the pathogenesis of disease. Cancer Lett 288:133-148
17. Barone I, Brusco L, Fuqua SA 2010 Estrogen receptor mutations and changes in downstream gene expression and signaling. Clin Cancer Res 16:2702-2708
18. Herynk MH, Fuqua SA 2004 Estrogen receptor mutations in human disease. Endocr Rev 25:869-898
19. Faus H, Haendler B 2006 Post-translational modifications of steroid receptors. Biomed Pharmacother 60:520-528
20. Hall JM, McDonnell DP 2005 Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting. Mol Interv 5:343-357
21. Lannigan DA 2003 Estrogen receptor phosphorylation. Steroids 68:1-9
22. Ward RD, Weigel NL 2009 Steroid receptor phosphorylation: assigning function to site-specific phosphorylation. Biofactors 35:528-536
23. Popov VM, Wang C, Shirley LA, Rosenberg A, Li S, Nevalainen M, Fu M, Pestell RG 2007 The functional significance of nuclear receptor acetylation. Steroids 72:221-230
24. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM 1995 The nuclear receptor superfamily: the second decade. Cell 83:835-839
25. Zhao C, Dahlman-Wright K, Gustafsson JA 2008 Estrogen receptor β: an overview and update. Nucl Recept Signal 6:e003
26. Tsai MJ, O'Malley BW 1994 Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 63:451-486
27. Tora L, White J, Brou C, Tasset D, Webster N, Scheer E, Chambon P 1989 The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell 59:477-487
28. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA 1996 Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 93:5925-5930
29. Mosselman S, Polman J, Dijkema R 1996 ER β: identification and characterization of a novel human estrogen receptor. FEBS Lett 392:49-53
30. Zwart W, de Leeuw R, Rondaij M, Neefjes J, Mancini MA, Michalides R 2010 The hinge region of the human estrogen receptor determines functional synergy between AF-1 and AF-2 in the quantitative response to estradiol and tamoxifen. J Cell Sci 123:1253-1261
31. Nilsson S, Mäkelä S, Treuter E, Tujague M, Thomsen J, Andersson G, Enmark E, Pettersson K, Warner M, Gustafsson JA 2001 Mechanisms of estrogen action. Physiol Rev 81:1535-1565
32. Magee PJ, Rowland IR 2004 Phyto-oestrogens, their mechanism of action: current evidence for a role in breast and prostate cancer. Br J Nutr 91:513-531
33. Miodini P, Fioravanti L, Di Fronzo G, Cappelletti V 1999 The two phyto-oestrogens genistein and quercetin exert different effects on oestrogen receptor function. Br J Cancer 80:1150-1155
34. Jordan VC, O'Malley BW 2007 Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J Clin Oncol 25:5815-5824
35. Smith CL, O'Malley BW 2004 Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 25:45-71
36. Dowsett M, Nicholson RI, Pietras RJ 2005 Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance. Breast Cancer Res Treat 93(Suppl 1):S11-S18
37. Wakeling AE, Dukes M, Bowler J 1991 A potent specific pure antiestrogen with clinical potential. Cancer Res 51:3867-3873
38. Dahlman-Wright K, Cavailles V, Fuqua SA, Jordan VC, Katzenellenbogen JA, Korach KS, Maggi A, Muramatsu M, Parker MG, Gustafsson JA 2006 International Union of Pharmacology. LXIV. Estrogen receptors. Pharmacol Rev 58:773-781
39. Hewitt SC, Harrell JC, Korach KS 2005 Lessons in estrogen biology from knockout and transgenic animals. Annu Rev Physiol 67:285-308
40. Krege JH, Hodgin JB, Couse JF, Enmark E, Warner M, Mahler JF, Sar M, Korach KS, Gustafsson JA, Smithies O 1998 Generation and reproductive phenotypes of mice lacking estrogen receptor β. Proc Natl Acad Sci USA 95:15677-15682
41. Lubahn DB, Moyer JS, Golding TS, Couse JF, Korach KS, Smithies O 1993 Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc Natl Acad Sci USA 90:11162-11166
42. Tee MK, Rogatsky I, Tzagarakis-Foster C, Cvoro A, An J, Christy RJ, Yamamoto KR, Leitman DC 2004 Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors α and β. Mol Biol Cell 15:1262-1272
43. Monroe DG, Getz BJ, Johnsen SA, Riggs BL, Khosla S, Spelsberg TC 2003 Estrogen receptor isoform-specific regulation of endogenous gene expression in human osteoblastic cell lines expressing either ERα or ERβ. J Cell Biochem 90:315-326
44. Shim GJ, Wang L, Andersson S, Nagy N, Kis LL, Zhang Q, Mäkelä S, Warner M, Gustafsson JA 2003 Disruption of the estrogen receptor β gene in mice causes myeloprolifer- ative disease resembling chronic myeloid leukemia with lymphoid blast crisis. Proc Natl Acad Sci USA 100:6694-6699
45. Vivar OI, Zhao X, Saunier EF, Griffin C, Mayba OS, Tagliaferri M, Cohen I, Speed TP, Leitman DC 2010 Estrogen receptor β binds to and regulates three distinct classes of target genes. J Biol Chem 285:22059-22066
46. Cowley SM, Hoare S, Mosselman S, Parker MG 1997 Estrogen receptorsα andβ form heterodimers on DNA.J Biol Chem 272:19858-19862
47. Papoutsi Z, Zhao C, Putnik M, Gustafsson JA, Dahlman-Wright K 2009 Binding of estrogen receptor α/β heterodimers to chromatin in MCF-7 cells. J Mol Endocrinol 43:65-72
48. Gougelet A, Mueller SO, Korach KS, Renoir JM 2007 Oestrogen receptors pathways to oestrogen responsive elements: the transactivation function-1 acts as the keystone of oestrogen receptor (ER)β-mediated transcriptional repression of ERα. J Steroid Biochem Mol Biol 104:110-122
49. Hall JM, McDonnell DP 1999 The estrogen receptor β-isoform (ERβ) of the human estrogen receptor modulates ERα transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 140:5566-5578
50. Liu MM, Albanese C, Anderson CM, Hilty K, Webb P, Uht RM, Price Jr RH, Pestell RG, Kushner PJ 2002 Opposing action of estrogen receptors α and β on cyclin D1 gene expression. J Biol Chem 277:24353-24360
51. Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC 2004 Estrogen receptor β inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res 64:423-428
52. Kos M, Reid G, Denger S, Gannon F 2001 Minireview: genomic organization of the human ERα gene promoter region. Mol Endocrinol 15:2057-2063
53. Trivedi S, Piccart M, Muquardt C, Gilot N, Hadiy S, Patel D, Leclercq G 1996 Tamoxifen aziridine labeling of the estrogen receptor-potential utility in detecting biologically aggressive breast tumors. Breast Cancer Res Treat 40:231-241
54. Denger S, Reid G, Kos M, Flouriot G, Parsch D, Brand H, Korach KS, Sonntag-Buck V, Gannon F 2001 ERα gene expression in human primary osteoblasts: evidence for the expression of two receptor proteins. Mol Endocrinol 15:2064-2077
55. Murphy AJ, Guyre PM, Wira CR, Pioli PA 2009 Estradiol regulates expression of estrogen receptor ERα46 in human macrophages. PLoS One 4:e5539
56. Li L, Haynes MP, Bender JR 2003 Plasma membrane localization and function of the estrogen receptor α variant (ER46) in human endothelial cells. Proc Natl Acad Sci USA 100:4807-4812
57. Flouriot G, Brand H, Denger S, Metivier R, Kos M, Reid G, Sonntag-Buck V, Gannon F 2000 Identification of a new isoform of the human estrogen receptor-α (hER-α) that is encoded by distinct transcripts and that is able to repress hER-α activation function 1. EMBO J 19:4688-4700
58. Penot G, Le Péron C, Mérot Y, Grimaud-Fanouillère E, Ferrière F, Boujrad N, Kah O, Saligaut C, Ducouret B, Métivier R, Flouriot G 2005 The human estrogen receptor- α isoform hERα46 antagonizes the proliferative influence of hERα66 in MCF7 breast cancer cells. Endocrinology 146:5474-5484
59. Garcia T, Lehrer S, Bloomer WD, Schachter B 1988 A variant estrogen receptor messenger ribonucleic acid is associated with reduced levels of estrogen binding in human mammary tumors. Mol Endocrinol 2:785-791
60. Fuqua SA, Fitzgerald SD, Allred DC, Elledge RM, Nawaz Z, McDonnell DP, O'Malley BW, Greene GL, McGuire WL 1992 Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors. Cancer Res 52:483-486
61. McGuire WL, Chamness GC, Fuqua SA 1991 Estrogen receptor variants in clinical breast cancer. Mol Endocrinol 5:1571-1577
62. Klinge CM, Riggs KA, Wickramasinghe NS, Emberts CG, McConda DB, Barry PN, Magnusen JE 2010 Estrogen receptor α 46 is reduced in tamoxifen resistant breast cancer cells and re-expression inhibits cell proliferation and estrogen receptor α 66-regulated target gene transcription. Mol Cell Endocrinol 323:268-276
63. Wang Z, Zhang X, Shen P, Loggie BW, Chang Y, Deuel TF 2005 Identification, cloning, and expression of human estrogen receptor-α36, a novel variant of human estrogen receptor-α66. Biochem Biophys Res Commun 336:1023-1027
64. Wang Z, Zhang X, Shen P, Loggie BW, Chang Y, Deuel TF 2006 A variant of estrogen receptor-α, hER-α36: transduction of estrogen- and antiestrogen-dependent membrane- initiated mitogenic signaling. Proc Natl Acad Sci USA 103:9063-9068
65. Zhang XT, Kang LG, Ding L, Vranic S, Gatalica Z, Wang ZY 2011 A positive feedback loop of ER-α36/EGFR promotes malignant growth of ER-negative breast cancer cells. Oncogene 30:770-780
66. Shi L, Dong B, Li Z, Lu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Wang Z, Xie Y 2009 Expression of ER-α36, a novel variant of estrogen receptor α, and resistance to tamoxifen treatment in breast cancer. J Clin Oncol 27:3423-3429
67. Moore JT, McKee DD, Slentz-Kesler K, Moore LB, Jones SA, Horne EL, Su JL, Kliewer SA, Lehmann JM, Willson TM1998 Cloning and characterization of human estrogen receptor β isoforms. Biochem Biophys Res Commun 247:75-78
68. Saunders PT, Millar MR, Macpherson S, Irvine DS, Groome NP, Evans LR, Sharpe RM, Scobie GA 2002 ERβ1 and the ERβ2 splice variant (ERβcx/β2) are expressed in distinct cell populations in the adult human testis. J Clin Endocrinol Metab 87:2706-2715
69. Davies MP, O'Neill PA, Innes H, Sibson DR, Prime W, Holcombe C, Foster CS 2004 Correlation of mRNA for oestrogen receptor β splice variants ERβ1, ERβ2/ERβcx and ERβ5 with outcome in endocrine-treated breast cancer. J Mol Endocrinol 33:773-782
70. Skliris GP, Leygue E, Curtis-Snell L, Watson PH, Murphy LC 2006 Expression of oestrogen receptor- β in oestrogen receptor-α negative human breast tumours. Br J Cancer 95:616-626
71. Gougelet A, Bouclier C, Marsaud V, Maillard S, Mueller SO, Korach KS, Renoir JM 2005 Estrogen receptor α and β subtype expression and transactivation capacity are differentially affected by receptor-, hsp90- and immunophi- lin-ligands in human breast cancer cells. J Steroid Biochem Mol Biol 94:71-81
72. Jensen EV 1991 Steroid hormone receptors. Curr Top Pathol 83:365-431
73. Sabbah M, Redeuilh G, Secco C, Baulieu EE 1987 The binding activity of estrogen receptor to DNA and heat shock protein(Mr90,000) is dependent on receptor-bound metal. J Biol Chem 262:8631-8635
74. Perissi V, Jepsen K, Glass CK, Rosenfeld MG 2010 Deconstructing repression: evolving models of co-repressor action. Nat Rev Genet 11:109-123
75. Lonard DM, O'Malley BW 2006 The expanding cosmos of nuclear receptor coactivators. Cell 125:411-414
76. Robyr D, Wolffe AP, Wahli W 2000 Nuclear hormone receptor coregulators in action: diversity for shared tasks. Mol Endocrinol 14:329-347
77. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M 2000 Cofactor dynamics and sufficiency in estrogen receptorregulated transcription. Cell 103:843-852
78. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687-1717
79. Gradishar WJ 2005 The future of breast cancer: the role of prognostic factors. Breast Cancer Res Treat 89(Suppl 1): S17-S26
80. York B, O'Malley BW 2010 Steroid receptor coactivator (SRC) family: masters of systems biology. J Biol Chem 285:38743-38750
81. Kirkegaard T, McGlynn LM, Campbell FM, Müller S, Tovey SM, Dunne B, Nielsen KV, Cooke TG, Bartlett JM 2007 Amplified in breast cancer 1 in human epidermal growth factor receptor-positive tumors of tamoxifentreated breast cancer patients. Clin Cancer Res 13:1405-1411
82. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM, Schiff R 2003 Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95:353-361
83. Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM, Webb P 2000 Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol 74:311-317
84. O'Lone R, Frith MC, Karlsson EK, Hansen U 2004 Genomic targets of nuclear estrogen receptors. Mol Endocrinol 18:1859-1875
85. Saville B, Wormke M, Wang F, Nguyen T, Enmark E, Kuiper G, Gustafsson JA, Safe S 2000 Ligand-, cell-, and estrogen receptor subtype (α/β)-dependent activation at GC-rich (Sp1) promoter elements. J Biol Chem 275:5379-5387
86. Björnström L, Sjöberg M 2004 Estrogen receptor-dependent activation of AP-1 via non-genomic signalling. Nucl Recept 2:3
87. Quaedackers ME, van den Brink CE, van der Saag PT, Tertoolen LG 2007 Direct interaction between estrogen receptorα and NF-κBin the nucleus of living cells. MolCell Endocrinol 273:42-50
88. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ, Scanlan TS 1997 Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science 277:1508-1510
89. Johnston SR, Lu B, Scott GK, Kushner PJ, Smith IE, Dowsett M, Benz CC 1999 Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. Clin Cancer Res 5:251-256
90. Schiff R, Reddy P, Ahotupa M, Coronado-Heinsohn E, Grim M, Hilsenbeck SG, Lawrence R, Deneke S, Herrera R, Chamness GC, Fuqua SA, Brown PH, Osborne CK 2000 Oxidative stress and AP-1 activity in tamoxifenresistant breast tumors in vivo. J Natl Cancer Inst 92:1926-1934
91. Zhou Y, Yau C, Gray JW, Chew K, Dairkee SH, Moore DH, Eppenberger U, Eppenberger-Castori S, Benz CC 2007 Enhanced NFκB and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer 7:59
92. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon P 1995 Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270:1491-1494
93. Tremblay A, Tremblay GB, Labrie F, Giguère V 1999 Ligand- independent recruitment of SRC-1 to estrogen receptor β through phosphorylation of activation function AF-1. Mol Cell 3:513-519
94. Sauvé K, Lepage J, Sanchez M, Heveker N, Tremblay A 2009 Positive feedback activation of estrogen receptors by the CXCL12-CXCR4 pathway. Cancer Res 69:5793-5800
95. Rhodes LV, Short SP, Neel NF, Salvo VA, Zhu Y, Elliott S, Wei Y, Yu D, Sun M, Muir SE, Fonseca JP, Bratton MR, Segar C, Tilghman SL, Sobolik-Delmaire T, Horton LW, Zaja-Milatovic S, Collins-Burow BM, Wadsworth S, Beckman BS, Wood CE, Fuqua SA, Nephew KP, Dent P, Worthylake RA, Curiel TJ, Hung MC, Richmond A, Burow ME 2011 Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Res 71:603-613
96. Hammes SR, Levin ER 2007 Extranuclear steroid receptors: nature and actions. Endocr Rev 28:726-741
97. Olde B, Leeb-Lundberg LM 2009 GPR30/GPER1: searching for a role in estrogen physiology. Trends Endocrinol Metab 20:409-416
98. Pappas TC, Gametchu B, Watson CS 1995 Membrane estrogen receptors identified by multiple antibody labeling and impeded-ligand binding. FASEB J 9:404-410
99. Levin ER 2009 Plasma membrane estrogen receptors. Trends Endocrinol Metab 20:477-482
100. Razandi M, Pedram A, Merchenthaler I, Greene GL, Levin ER 2004 Plasma membrane estrogen receptors exist and functions as dimers. Mol Endocrinol 18:2854-2865
101. Acconcia F, Manavathi B, Mascarenhas J, Talukder AH, Mills G, Kumar R 2006 An inherent role of integrin-linked kinase-estrogen receptor α interaction in cell migration. Cancer Res 66:11030-11038
102. Björnström L, Sjöberg M 2005 Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol 19:833-842
103. Castoria G, Migliaccio A, Bilancio A, Di Domenico M, de Falco A, Lombardi M, Fiorentino R, Varricchio L, Barone MV, Auricchio F 2001 PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells. EMBO J 20:6050-6059
104. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK 2000 Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407:538-541
105. Song RX, Zhang Z, Santen RJ 2005 Estrogen rapid action via protein complex formation involving ERα and Src. Trends Endocrinol Metab 16:347-353
106. Song RX, Barnes CJ, Zhang Z, Bao Y, Kumar R, Santen RJ 2004 The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor α to the plasma membrane. Proc Natl Acad Sci USA 101:2076-2081
107. Kumar P, Wu Q, Chambliss KL, Yuhanna IS, Mumby SM, Mineo C, Tall GG, Shaul PW 2007 Direct interactions with Gα i and Gβγmediate nongenomic signaling by estrogen receptor α. Mol Endocrinol 21:1370-1380
108. Cabodi S, Moro L, Baj G, Smeriglio M, Di Stefano P, Gippone S, Surico N, Silengo L, Turco E, Tarone G, Defilippi P 2004 p130Cas interacts with estrogen receptor α and modulates non-genomic estrogen signaling in breast cancer cells. J Cell Sci 117:1603-1611
109. Lu Q, Pallas DC, Surks HK, Baur WE, Mendelsohn ME, Karas RH 2004 Striatin assembles a membrane signaling complex necessary for rapid, nongenomic activation of endothelial NO synthase by estrogen receptor α. Proc Natl Acad Sci USA 101:17126-17131
110. Fernando RI, Wimalasena J 2004 Estradiol abrogates apoptosis in breast cancer cells through inactivation of BAD: Ras-dependent nongenomic pathways requiring signaling through ERK and Akt. Mol Biol Cell 15:3266-3284
111. Pedram A, Razandi M, Evinger AJ, Lee E, Levin ER 2009 Estrogen inhibits ATR signaling to cell cycle checkpoints and DNA repair. Mol Biol Cell 20:3374-3389
112. Azuma K, Urano T, Horie-Inoue K, Hayashi S, Sakai R, Ouchi Y, Inoue S 2009 Association of estrogen receptor α and histone deacetylase 6 causes rapid deacetylation of tubulin in breast cancer cells. Cancer Res 69:2935-2940
113. Catalano S, Barone I, Giordano C, Rizza P, Qi H, Gu G, Malivindi R, Bonofiglio D, Andò S 2009 Rapid estradiol/ ERα signaling enhances aromatase enzymatic activity in breast cancer cells. Mol Endocrinol 23:1634-1645
114. Chambliss KL, Yuhanna IS, Anderson RG, Mendelsohn ME, Shaul PW 2002 ERβ has nongenomic action in caveolae. Mol Endocrinol 16:938-946
115. Migliaccio A, Castoria G, Di Domenico M, de Falco A, Bilancio A, Lombardi M, Barone MV, Ametrano D, Zannini MS, Abbondanza C, Auricchio F 2000 Steroidinduced androgen receptor-oestradiol receptor β-Src complex triggers prostate cancer cell proliferation. EMBO J 19:5406-5417
116. Ordóñez-Morán P, Muñoz A 2009 Nuclear receptors: genomic and non-genomic effects converge. Cell Cycle 8:1675-1680
117. MacGregor JI, Jordan VC 1998 Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev 50:151-196
118. Nawaz Z, Lonard DM, Dennis AP, Smith CL, O'Malley BW 1999 Proteasome-dependent degradation of the human estrogen receptor. Proc Natl Acad Sci USA 96:1858-1862
119. Lonard DM, Nawaz Z, Smith CL, O'Malley BW 2000 The 26S proteasome is required for estrogen receptor-α and coactivator turnover and for efficient estrogen receptor-α transactivation. Mol Cell 5:939-948
120. Wijayaratne AL, McDonnell DP 2001 The human estrogen receptor-α is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J Biol Chem 276:35684-35692
121. Marsaud V, Gougelet A, Maillard S, Renoir JM 2003 Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor α (ERα), differentially affect ERα extractability, proteasome- mediated stability, and transcriptional activity in human breast cancer cells. Mol Endocrinol 17:2013-2027
122. McDonnell DP, Dana SL, Hoener PA, Lieberman BA, Imhof MO, Stein RB 1995 Cellular mechanisms which distinguish between hormone- and antihormone-activated estrogen receptor. Ann NY Acad Sci 761:121-137
123. Tzukerman MT, Esty A, Santiso-Mere D, Danielian P, Parker MG, Stein RB, Pike JW, McDonnell DP 1994 Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol 8:21-30
124. Jensen EV, Jordan VC 2003 The estrogen receptor: a model for molecular medicine. Clin Cancer Res 9:1980-1989
125. Johnston SR, Dowsett M 2003 Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat Rev Cancer 3:821-831
126. Jordan VC 2004 Aromatase inhibitors that regulate estrogen target tissues selectively? Bone 34:372-375
127. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL 2005 Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCICCTGMA.17. J Natl Cancer Inst 97:1262-1271
128. Musgrove EA, Sutherland RL 2009 Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9:631-643
129. Roodi N, Bailey LR, Kao WY, Verrier CS, Yee CJ, Dupont WD, Parl FF 1995 Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. J Natl Cancer Inst 87:446-451
130. O'Malley BW, Qin J, Lanz RB 2008 Cracking the coregulator codes. Curr Opin Cell Biol 20:310-315
131. Li X, Lonard DM, Jung SY, Malovannaya A, Feng Q, Qin J, Tsai SY, Tsai MJ, O'Malley BW 2006 The SRC-3/AIB1 coactivator is degraded in a ubiquitin- and ATP-independent manner by the REGproteasome. Cell 124:381-392
132. Margueron R, Duong V, Castet A, Cavaillès V 2004 Histone deacetylase inhibition and estrogen signalling in human breast cancer cells. Biochem Pharmacol 68:1239-1246
133. Sanchez M, Picard N, Sauvé K, Tremblay A 2010 Challenging estrogen receptor β with phosphorylation. Trends Endocrinol Metab 21:104-110
134. Auricchio F, Migliaccio A 1980 In vitro inactivation of oestrogen receptor by nuclei: prevention by phosphatase inhibitors. FEBS Lett 117:224-226
135. Auricchio F, Migliaccio A, Castoria G, Rotondi A, Lastoria S 1984 Direct evidence of in vitro phosphorylation-dephosphorylation of the estradiol-17β receptor. Role of Ca2+-calmodulin in the activation of hormone binding sites. J Steroid Biochem 20:31-35
136. Thomas RS, Sarwar N, Phoenix F, Coombes RC, Ali S 2008 Phosphorylation at serines 104 and 106 by Erk1/2 MAPK is important for estrogen receptor-α activity. J Mol Endocrinol 40:173-184
137. Medunjanin S, Hermani A, DeServi B, Grisouard J, Rincke G, Mayer D 2005 Glycogen synthase kinase-3 interacts with and phosphorylates estrogen receptor α and is involved in the regulation of receptor activity. J Biol Chem 280:33006-33014
138. Rogatsky I, Trowbridge JM, Garabedian MJ 1999 Potentiation of human estrogen receptor α transcriptional activation through phosphorylation of serines 104 and 106 by the cyclin A-CDK2 complex. J Biol Chem 274:22296-22302
139. Masuhiro Y, Mezaki Y, Sakari M, Takeyama K, Yoshida T, Inoue K, Yanagisawa J, Hanazawa S, O'malley BW, Kato S 2005 Splicing potentiation by growth factor signals via estrogen receptor phosphorylation. Proc Natl Acad Sci USA 102:8126-8131
140. Sheeler CQ, Singleton DW, Khan SA 2003 Mutation of serines 104, 106, and 118 inhibits dimerization of the human estrogen receptor in yeast. Endocr Res 29:237-255
141. Cheng J, Zhang C, Shapiro DJ 2007 A functional serine 118 phosphorylation site in estrogen receptor-α is required for down-regulation of gene expression by 17β-estradiol and 4-hydroxytamoxifen. Endocrinology 148:4634-4641
142. Dutertre M, Smith CL 2003 Ligand-independent interactions of p160/steroid receptor coactivators and CREBbinding protein (CBP) with estrogen receptor-α: regulation by phosphorylation sites in the A/B region depends on other receptor domains. Mol Endocrinol 17:1296-1314
143. Shah YM, Rowan BG 2005 The Src kinase pathway promotes tamoxifen agonist action in Ishikawa endometrial cells through phosphorylation-dependent stabilization of estrogen receptor (α) promoter interaction and elevated steroid receptor coactivator 1 activity. Mol Endocrinol 19:732-748
144. Bunone G, Briand PA, Miksicek RJ, Picard D 1996 Activation of the unliganded estrogen receptor by EGFinvolves the MAP kinase pathway and direct phosphorylation. EMBO J 15:2174-2183
145. Ali S, Metzger D, Bornert JM, Chambon P 1993 Modulation of transcriptional activation by ligand-dependent phosphorylation of the human oestrogen receptor A/B region. EMBO J 12:1153-1160
146. Chen D, Washbrook E, Sarwar N, Bates GJ, Pace PE, Thirunuvakkarasu V, Taylor J, Epstein RJ, Fuller-Pace FV, Egly JM, Coombes RC, Ali S 2002 Phosphorylation of human estrogen receptor α at serine 118 by two distinct signal transduction pathways revealed by phosphorylation- specific antisera. Oncogene 21:4921-4931
147. Park KJ, Krishnan V, O'Malley BW, Yamamoto Y, Gaynor RB 2005 Formation of an IKKα-dependent transcription complex is required for estrogen receptor-mediated gene activation. Mol Cell 18:71-82
148. Weitsman GE, Li L, Skliris GP, Davie JR, Ung K, Niu Y, Curtis-Snell L, Tomes L, Watson PH, Murphy LC 2006 Estrogen receptor-α phosphorylated at Ser118 is present at the promoters of estrogen-regulated genes and is not altered due to HER-2 overexpression. Cancer Res 66:10162-10170
149. González L, Zambrano A, Lazaro-Trueba I, Lopéz E, González JJ, Martín-Pérez J, Aranda A 2009 Activation of the unliganded estrogen receptor by prolactin in breast cancer cells. Oncogene 28:1298-1308
150. Arnold SF, Obourn JD, Jaffe H, Notides AC 1994 Serine 167 is the major estradiol-induced phosphorylation site on the human estrogen receptor. Mol Endocrinol 8:1208-1214
151. Joel PB, Smith J, Sturgill TW, Fisher TL, Blenis J, Lannigan DA 1998 pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167. Mol Cell Biol 18:1978-1984
152. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H 2001 Phosphatidylinositol 3-kinase/ AKT-mediated activation of estrogen receptor α: a new model for anti-estrogen resistance. J Biol Chem 276:9817-9824
153. Yamnik RL, Digilova A, Davis DC, Brodt ZN, Murphy CJ, Holz MK 2009 S6 kinase 1 regulates estrogen receptorα in control of breast cancer cell proliferation. J Biol Chem284:6361-6369
154. Yamnik RL, Holz MK 2010 mTOR/S6K1 and MAPK/RSK signaling pathways coordinately regulate estrogen receptor α serine 167 phosphorylation. FEBS Lett 584:124-128
155. Chen D, Pace PE, Coombes RC, Ali S 1999 Phosphorylation of human estrogen receptor α by protein kinase A regulates dimerization. Mol Cell Biol 19:1002-1015
156. Tsai HW, Katzenellenbogen JA, Katzenellenbogen BS, Shupnik MA 2004 Protein kinase A activation of estrogen receptor α transcription does not require proteasome activity and protects the receptor from ligand-mediated degradation. Endocrinology 145:2730-2738
157. Michalides R, Griekspoor A, Balkenende A, Verwoerd D, Janssen L, Jalink K, Floore A, Velds A, van't Veer L, Neefjes J 2004 Tamoxifen resistance by a conformational arrest of the estrogen receptor α after PKA activation in breast cancer. Cancer Cell 5:597-605
158. Tharakan R, Lepont P, Singleton D, Kumar R, Khan S 2008 Phosphorylation of estrogen receptor α, serine residue 305 enhances activity. Mol Cell Endocrinol 295:70-78
159. Balasenthil S, Barnes CJ, Rayala SK, Kumar R 2004 Estrogen receptor activation at serine 305 is sufficient to upregulate cyclin D1 in breast cancer cells. FEBS Lett 567:243-247
160. Wang RA, Mazumdar A, Vadlamudi RK, Kumar R 2002 P21-activated kinase-1 phosphorylates and transactivates estrogen receptor-α and promotes hyperplasia in mammary epithelium. EMBO J 21:5437-5447
161. Zwart W, Griekspoor A, Berno V, Lakeman K, Jalink K, Mancini M, Neefjes J, Michalides R 2007 PKA-induced resistance to tamoxifen is associated with an altered ori- entation of ERα towards co-activator SRC-1. EMBO J 26:3534-3544
162. Kok M, Zwart W, Holm C, Fles R, Hauptmann M, Van't Veer LJ, Wessels LF, Neefjes J, Stål O, Linn SC, Landberg G, Michalides R 2011 PKA-induced phosphorylation of ERα at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer. Breast Cancer Res Treat 125:1-12
163. Barone I, Iacopetta D, Covington KR, Cui Y, Tsimelzon A, Beyer A, Andò S, Fuqua SA 2010 Phosphorylation of the mutant K303R estrogen receptor α at serine 305 affects aromatase inhibitor sensitivity. Oncogene 29:2404-2414
164. Giordano C, Cui Y, Barone I, Ando S, Mancini MA, Berno V, Fuqua SA 2010 Growth factor-induced resistance to tamoxifen is associated with a mutation of estrogen receptor α and its phosphorylation at serine 305. Breast Cancer Res Treat 119:71-85
165. Barone I, Cui Y, Herynk MH, Corona-Rodriguez A, Giordano C, Selever J, Beyer A, Andò S, Fuqua SA 2009 Expression of the K303R estrogen receptor-α breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3K/Akt kinase pathway. Cancer Res 69:4724-4732
166. Tremblay GB, Tremblay A, Copeland NG, Gilbert DJ, Jenkins NA, Labrie F, Giguère V 1997 Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor β. Mol Endocrinol 11:353-365
167. Bhat RA, Harnish DC, Stevis PE, Lyttle CR, Komm BS 1998 A novel human estrogen receptor β: identification and functional analysis of additional N-terminal amino acids. J Steroid Biochem Mol Biol 67:233-240
168. Cheng X, Cole RN, Zaia J, Hart GW 2000 Alternative O-glycosylation/O-phosphorylation of the murine estrogen receptor β. Biochemistry 39:11609-11620
169. Cheng X, Hart GW 2001 Alternative O-glycosylation/Ophosphorylation of serine-16 in murine estrogen receptor β: post-translational regulation of turnover and transactivation activity. J Biol Chem 276:10570-10575
170. Picard N, Charbonneau C, Sanchez M, Licznar A, Busson M, Lazennec G, Tremblay A 2008 Phosphorylation of activation function-1 regulates proteasome-dependent nuclear mobility and E6-associated protein ubiquitin ligase recruitment to the estrogen receptor β. Mol Endocrinol 22:317-330
171. Tremblay A, Giguère V 2001 Contribution of steroid receptor coactivator-1 and CREB binding protein in ligandindependent activity of estrogen receptor β. J Steroid Biochem Mol Biol 77:19-27
172. St-Laurent V, Sanchez M, Charbonneau C, Tremblay A 2005 Selective hormone-dependent repression of estrogen receptor β by a p38-activated ErbB2/ErbB3 pathway. J Steroid Biochem Mol Biol 94:23-37
173. Sanchez M, Sauvé K, Picard N, Tremblay A 2007 The hormonal response of estrogen receptor β is decreased by the phosphatidylinositol 3-kinase/Akt pathway via a phosphorylation- dependent release of CREB-binding protein. J Biol Chem 282:4830-4840
174. Tremblay GB, Tremblay A, Labrie F, Giguère V 1998 Ligand- independent activation of the estrogen receptors α and β by mutations of a conserved tyrosine can be abolished by antiestrogens. Cancer Res 58:877-881
175. Auricchio F, Di Domenico M, Migliaccio A, Castoria G, Bilancio A 1995 The role of estradiol receptor in the proliferative activity of vanadate on MCF-7 cells. Cell Growth Differ 6:105-113
176. Power RF, Mani SK, Codina J, Conneely OM, O'Malley BW 1991 Dopaminergic and ligand-independent activation of steroid hormone receptors. Science 254:1636-1639
177. Ikeda K, Ogawa S, Tsukui T, Horie-Inoue K, Ouchi Y, Kato S, Muramatsu M, Inoue S 2004 Protein phosphatase 5 is a negative regulator of estrogen receptor-mediated transcription. Mol Endocrinol 18:1131-1143
178. Singh BN, Zhang G, Hwa YL, Li J, Dowdy SC, Jiang SW 2010 Nonhistone protein acetylation as cancer therapy targets. Expert Rev Anticancer Ther 10:935-954
179. Chen H, Lin RJ, Xie W, Wilpitz D, Evans RM 1999 Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase. Cell 98:675-686
180. Kim MY, Hsiao SJ, Kraus WL 2001 Arole for coactivators and histone acetylation in estrogen receptor α-mediated transcription initiation. EMBO J 20:6084-6094
181. Kim MY, Woo EM, Chong YT, Homenko DR, Kraus WL 2006 Acetylation of estrogen receptor α by p300 at lysines 266 and 268 enhances the deoxyribonucleic acid binding and transactivation activities of the receptor. Mol Endocrinol 20:1479-1493
182. Wang C, Fu M, Angeletti RH, Siconolfi-Baez L, Reutens AT, Albanese C, Lisanti MP, Katzenellenbogen BS, Kato S, Hopp T, Fuqua SA, Lopez GN, Kushner PJ, Pestell RG 2001 Direct acetylation of the estrogen receptor α hinge region by p300 regulates transactivation and hormone sensitivity. J Biol Chem 276:18375-18383
183. Ma Y, Fan S, Hu C, Meng Q, Fuqua SA, Pestell RG, Tomita YA, Rosen EM 2010 BRCA1 regulates acetylation and ubiquitination of estrogen receptor-α. Mol Endocrinol 24:76-90
184. Urbinati G, Marsaud V, Plassat V, Fattal E, Lesieur S, Renoir JM 2010 Liposomes loaded with histone deacetylase inhibitors for breast cancer therapy. Int J Pharm 397:184-193
185. Duong V, Licznar A, Margueron R, Boulle N, Busson M, Lacroix M, Katzenellenbogen BS, Cavaillès V, Lazennec G 2006 ERα and ERβ expression and transcriptional activity are differentially regulated by HDACinhibitors. Oncogene 25:1799-1806
186. Stenoien DL, Patel K, Mancini MG, Dutertre M, Smith CL, O'Malley BW, Mancini MA 2001 FRAP reveals that mobility of oestrogen receptor-α is ligand- and proteasomedependent. Nat Cell Biol 3:15-23
187. Reid G, Hübner MR, Métivier R, Brand H, Denger S, Manu D, Beaudouin J, Ellenberg J, Gannon F 2003 Cyclic, proteasome-mediated turnover of unliganded and liganded ERα on responsive promoters is an integral feature of estrogen signaling. Mol Cell 11:695-707
188. Nirmala PB, Thampan RV 1995 Ubiquitination of the rat uterine estrogen receptor: dependence on estradiol. Biochem Biophys Res Commun 213:24-31
189. Fan M, Park A, Nephew KP 2005 CHIP (carboxyl terminus of Hsc70-interacting protein) promotes basal and geldanamycin-induced degradation of estrogen receptor- α. Mol Endocrinol 19:2901-2914
190. Duong V, Boulle N, Daujat S, Chauvet J, Bonnet S, Neel H, Cavaillès V 2007 Differential regulation of estrogen receptor α turnover and transactivation by Mdm2 and stressinducing agents. Cancer Res 67:5513-5521
191. Alarid ET, Bakopoulos N, Solodin N 1999 Proteasomemediated proteolysis of estrogen receptor: a novel component in autologous down-regulation. Mol Endocrinol 13:1522-1534
192. Laïos I, Journé F, Nonclercq D, Vidal DS, Toillon RA, Laurent G, Leclercq G 2005 Role of the proteasome in the regulation of estrogen receptor α turnover and function in MCF-7 breast carcinoma cells. J Steroid Biochem Mol Biol 94:347-359
193. Zhang H, Sun L, Liang J, Yu W, Zhang Y, Wang Y, Chen Y, Li R, Sun X, Shang Y 2006 The catalytic subunit of the proteasome is engaged in the entire process of estrogen receptor-regulated transcription. EMBO J 25:4223-4233
194. Métivier R, Penot G, Hübner MR, Reid G, Brand H, Kos M, Gannon F 2003 Estrogen receptor-α directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 115:751-763
195. Li L, Li Z, Howley PM, Sacks DB 2006 E6AP and calmodulin reciprocally regulate estrogen receptor stability. J Biol Chem 281:1978-1985
196. Saji S, Okumura N, Eguchi H, Nakashima S, Suzuki A, Toi M, Nozawa Y, Saji S, Hayashi S 2001 MDM2enhances the function of estrogen receptor α in human breast cancer cells. Biochem Biophys Res Commun 281:259-265
197. Nakajima A, Maruyama S, Bohgaki M, Miyajima N, Tsukiyama T, Sakuragi N, Hatakeyama S 2007 Ligand-dependent transcription of estrogen receptorα is mediated by the ubiquitin ligase EFP. Biochem Biophys Res Commun 357:245-251
198. Shao W, Keeton EK, McDonnell DP, Brown M 2004 Coactivator AIB1 links estrogen receptor transcriptional activity and stability. Proc Natl Acad Sci USA 101:11599-11604
199. El Khissiin A, Leclercq G 1999 Implication of proteasome in estrogen receptor degradation. FEBS Lett 448:160-166
200. Long X, Nephew KP 2006 Fulvestrant (ICI 182,780)-dependent interacting proteins mediate immobilization and degradation of estrogen receptor-α. J Biol Chem 281:9607-9615
201. Berry NB, Fan M, Nephew KP 2008 Estrogen receptor-α hinge-region lysines 302 and 303 regulate receptor degradation by the proteasome. Mol Endocrinol 22:1535-1551
202. Eakin CM, Maccoss MJ, Finney GL, Klevit RE 2007 Estrogen receptor α is a putative substrate for the BRCA1 ubiquitin ligase. Proc Natl Acad Sci USA 104:5794-5799
203. Stanisiæ V, Malovannaya A, Qin J, Lonard DM, O'Malley BW 2009 OTU Domain-containing ubiquitin aldehydebinding protein 1 (OTUB1) deubiquitinates estrogen receptor (ER) α and affects ERα transcriptional activity. J Biol Chem 284:16135-16145
204. Tateishi Y, Sonoo R, Sekiya Y, Sunahara N, Kawano M, Wayama M, Hirota R, Kawabe Y, Murayama A, Kato S, Kimura K, Yanagisawa J 2006 Turning off estrogen receptor β-mediated transcription requires estrogen-dependent receptor proteolysis. Mol Cell Biol 26:7966-7976
205. Masuyama H, Hiramatsu Y 2004 Involvement of suppressor for Gal 1 in the ubiquitin/proteasome-mediated degradation of estrogen receptors. J Biol Chem 279:12020-12026
206. Sentis S, Le Romancer M, Bianchin C, Rostan MC, Corbo L 2005 Sumoylation of the estrogen receptor α hinge region regulates its transcriptional activity. Mol Endocrinol 19:2671-2684
207. Pradhan S, Chin HG, Estève PO, Jacobsen SE 2009 SET7/9 mediated methylation of non-histone proteins in mammalian cells. Epigenetics 4:383-387
208. Subramanian K, Jia D, Kapoor-Vazirani P, Powell DR, Collins RE, Sharma D, Peng J, Cheng X, Vertino PM 2008 Regulation of estrogen receptorα by the SET7 lysine methyltransferase. Mol Cell 30:336-347
209. Garbán HJ, Márquez-Garbán DC, Pietras RJ, Ignarro LJ 2005 Rapid nitric oxide-mediated S-nitrosylation of estrogen receptor: regulation of estrogen-dependent gene transcription. Proc Natl Acad Sci USA 102:2632-2636
210. Cheng X, Hart GW 2000 Glycosylation of the murine estrogen receptor-α. J Steroid Biochem Mol Biol 75:147-158
211. Jiang MS, Hart GW 1997 A subpopulation of estrogen receptors are modified by O-linked N-acetylglucosamine. J Biol Chem 272:2421-2428
212. Atsriku C, Britton DJ, Held JM, Schilling B, Scott GK, Gibson BW, Benz CC, Baldwin MA 2009 Systematic mapping of posttranslational modifications in human estrogen receptor-α with emphasis on novel phosphorylation sites. Mol Cell Proteomics 8:467-480
213. Pietras RJ, Szego CM 1977 Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells. Nature 265:69-72
214. Acconcia F, Ascenzi P, Fabozzi G, Visca P, Marino M 2004 S-palmitoylation modulates human estrogen receptor-α functions. Biochem Biophys Res Commun 316:878-883
215. Acconcia F, Ascenzi P, Bocedi A, Spisni E, Tomasi V, Trentalance A, Visca P, Marino M 2005 Palmitoylation-dependent estrogen receptor α membrane localization: regulation by 17β-estradiol. Mol Biol Cell 16:231-237
216. Galluzzo P, Ascenzi P, Bulzomi P, Marino M 2008 The nutritional flavanone naringenin triggers antiestrogenic effects by regulating estrogen receptorα-palmitoylation. Endocrinology 149:2567-2575
217. Pedram A, Razandi M, Sainson RC, Kim JK, Hughes CC, Levin ER 2007 A conserved mechanism for steroid receptor translocation to the plasma membrane. J Biol Chem 282:22278-22288
218. Marino M, Ascenzi P 2008 Membrane association of estrogen receptorα andβ influences 17β-estradiol-mediated cancer cell proliferation. Steroids 73:853-858
219. Galluzzo P, Caiazza F, Moreno S, Marino M 2007 Role of ERβ palmitoylation in the inhibition of human colon cancer cell proliferation. Endocr Relat Cancer 14:153-167
220. Auricchio F, Migliaccio A, Castoria G, Di Domenico M, Pagano M 1990 Phosphorylation of uterus estradiol receptor on tyrosine. Prog Clin Biol Res 322:133-155
221. Migliaccio A, Rotondi A, Auricchio F 1986 Estradiol receptor: phosphorylation on tyrosine in uterus and interaction with anti-phosphotyrosine antibody. EMBO J 5:2867-2872
222. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX, Slamon DJ 1995 HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10:2435-2446
223. Arnold SF, Obourn JD, Jaffe H, Notides AC 1995 Phos- phorylation of the human estrogen receptor on tyrosine 537 in vivo and by src family tyrosine kinases in vitro. Mol Endocrinol 9:24-33
224. Auricchio F, Migliaccio A, Castoria G 2008 Sex-steroid hormones and EGFsignalling in breast and prostate cancer cells: targeting the association of Src with steroid receptors. Steroids 73:880-884
225. Varricchio L, Migliaccio A, Castoria G, Yamaguchi H, de Falco A, Di Domenico M, Giovannelli P, Farrar W, Appella E, Auricchio F 2007 Inhibition of estradiol receptor/Src association and cell growth by an estradiol receptor α tyrosine- phosphorylated peptide. Mol Cancer Res 5:1213-1221
226. Likhite VS, Stossi F, Kim K, Katzenellenbogen BS, Katzenellenbogen JA 2006 Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity. Mol Endocrinol 20:3120-3132
227. Le Romancer M, Treilleux I, Leconte N, Robin-Lespinasse Y, Sentis S, Bouchekioua-Bouzaghou K, Goddard S, Gobert-Gosse S, Corbo L 2008 Regulation of estrogen rapid signaling through arginine methylation by PRMT1. Mol Cell 31:212-221
228. Le Romancer M, Treilleux I, Bouchekioua-Bouzaghou K, Sentis S, Corbo L 2010 Methylation, a key step for nongenomic estrogen signaling in breast tumors. Steroids 75:560-564
229. Zhang QX, Borg A, Wolf DM, Oesterreich S, Fuqua SA 1997 An estrogen receptor mutant with strong hormoneindependent activity from a metastatic breast cancer. Cancer Res 57:1244-1249
230. Cui Y, Zhang M, Pestell R, Curran EM, Welshons WV, Fuqua SA 2004 Phosphorylation of estrogen receptor α blocks its acetylation and regulates estrogen sensitivity. Cancer Res 64:9199-9208
231. Herynk MH, Hopp T, Cui Y, Niu A, Corona-Rodriguez A, Fuqua SA 2010 A hypersensitive estrogen receptor α mutation that alters dynamic protein interactions. Breast Cancer Res Treat 122:381-393
232. Herynk MH, Parra I, Cui Y, Beyer A, Wu MF, Hilsenbeck SG, Fuqua SA 2007 Association between the estrogen receptor α A908G mutation and outcomes in invasive breast cancer. Clin Cancer Res 13:3235-3243
233. Rayala SK, Talukder AH, Balasenthil S, Tharakan R, Barnes CJ, Wang RA, Aldaz CM, Khan S, Kumar R 2006 P21-activated kinase 1 regulation of estrogen receptor-α activation involves serine 305 activation linked with serine 118 phosphorylation. Cancer Res 66:1694-1701
234. Calligé M, Kieffer I, Richard-Foy H 2005 CSN5/Jab1 is involved in ligand-dependent degradation of estrogen receptor α by the proteasome. Mol Cell Biol 25:4349-4358
235. Valley CC, Métivier R, Solodin NM, Fowler AM, Mashek MT, Hill L, Alarid ET 2005 Differential regulation of estrogen- inducible proteolysis and transcription by the estrogen receptorαNterminus. Mol Cell Biol 25:5417-5428
236. Valley CC, Solodin NM, Powers GL, Ellison SJ, Alarid ET 2008 Temporalvariation in estrogen receptor-α protein turnover in the presence of estrogen. J Mol Endocrinol 40:23-34
237. García Pedrero JM, Del Rio B, Martínez-Campa C, Muramatsu M, Lazo PS, Ramos S 2002 Calmodulin is a selective modulator of estrogen receptors. Mol Endocrinol 16:947-960
238. Fernö M, Stål O, Baldetorp B, Hatschek T, Källström AC, Malmström P, Nordenskjöld B, Rydën S 2000 Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels. South Sweden Breast Cancer Group, and South-East Sweden Breast Cancer Group. Breast Cancer Res Treat 59:69-76
239. Henry JA, Nicholson S, Farndon JR, Westley BR, May FE 1988 Measurement of oestrogen receptor mRNA levels in human breast tumours. Br J Cancer 58:600-605
240. Pichon MF, Broet P, Magdelenat H, Delarue JC, Spyratos F, Basuyau JP, Saez S, Rallet A, Courriere P, Millon R, Asselain B 1996 Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers. Br J Cancer 73:1545-1551
241. Bergqvist J, Elmberger G, Ohd J, Linderholm B, Bjohle J, Hellborg H, Nordgren H, Borg AL, Skoog L, Bergh J 2006 Activated ERK1/2 and phosphorylated oestrogen receptor α are associated with improved breast cancer survival in women treated with tamoxifen. Eur J Cancer 42:1104-1112
242. Murphy LC, Niu Y, Snell L, Watson P 2004 Phosphoserine- 118 estrogen receptor-α expression is associated with better disease outcome in women treated with tamoxifen. Clin Cancer Res 10:5902-5906
243. Sarwar N, Kim JS, Jiang J, Peston D, Sinnett HD, Madden P, Gee JM, Nicholson RI, Lykkesfeldt AE, Shousha S, Coombes RC, Ali S 2006 Phosphorylation of ERα at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERα phosphorylation in breast cancer progression. Endocr Relat Cancer 13:851-861
244. Yamashita H, Nishio M, Toyama T, Sugiura H, Kondo N, Kobayashi S, Fujii Y, Iwase H 2008 Low phosphorylation of estrogen receptor α (ERα) serine 118 and high phosphorylation of ERα serine 167 improve survival in ERpositive breast cancer. Endocr Relat Cancer 15:755-763
245. Zoubir M, Mathieu MC, Mazouni C, Liedtke C, Corley L, Geha S, Bouaziz J, Spielmann M, Drusche F, Symmans WF, Delaloge S, Andre F 2008 Modulation of ER phosphorylation on serine 118 by endocrine therapy: a new surrogate marker for efficacy. Ann Oncol 19:1402-1406
246. Jiang J, Sarwar N, Peston D, Kulinskaya E, Shousha S, Coombes RC, Ali S 2007 Phosphorylation of estrogen receptor- α at Ser167 is indicative of longer disease-free and overall survival in breast cancer patients. Clin Cancer Res 13:5769-5776
247. Gee JM, Robertson JF, Gutteridge E, Ellis IO, Pinder SE, Rubini M, Nicholson RI 2005 Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer 12(Suppl 1):S99-S111
248. Kok M, Holm-Wigerup C, Hauptmann M, Michalides R, Stål O, Linn S, Landberg G 2009 Estrogen receptor-α phosphorylation at serine-118 and tamoxifen response in breast cancer. J Natl Cancer Inst 101:1725-1729
249. Skliris GP, Nugent ZJ, Rowan BG, Penner CR, Watson PH, Murphy LC 2010 A phosphorylation code for oestrogen receptor α predicts clinical outcome to endocrine therapy in breast cancer. Endocr Relat Cancer 17:589-597
250. Yamashita H, Nishio M, Kobayashi S, Ando Y, Sugiura H, Zhang Z, Hamaguchi M, Mita K, Fujii Y, Iwase H 2005 Phosphorylation of estrogen receptor α serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer. Breast Cancer Res 7:R753-R764
251. Yamashita H, Takahashi S, Ito Y, Yamashita T, Ando Y, Toyama T, Sugiura H, Yoshimoto N, Kobayashi S, Fujii Y, Iwase H 2009 Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer. Cancer Sci 100:2028-2033
252. Skliris GP, Rowan BG, Al-Dhaheri M, Williams C, Troup S, Begic S, Parisien M, Watson PH, Murphy LC 2009 Immunohistochemical validation of multiple phospho-specific epitopes for estrogen receptor α (ERα) in tissue microarrays of ERα positivehumanbreast carcinomas. Breast Cancer Res Treat 118:443-453
253. Generali D, Buffa FM, Berruti A, Brizzi MP, Campo L, Bonardi S, Bersiga A, Allevi G, Milani M, Aguggini S, Papotti M, Dogliotti L, Bottini A, Harris AL, Fox SB 2009 Phosphorylated ERα, HIF-1α, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer. J Clin Oncol 27:227-234
254. Miller WR, Hulme MJ, Bartlett JM, MacCallum J, Dixon JM 1997 Changes in messenger RNAexpression of protein kinase A regulatory subunit iα in breast cancer patients treated with tamoxifen. Clin Cancer Res 3:2399-2404
255. Bostner J, Ahnström Waltersson M, Fornander T, Skoog L, Nordenskjöld B, Stål O 2007 Amplification of CCND1 and PAK1as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer. Oncogene 26:6997-7005
256. Holm C, Rayala S, Jirström K, Stål O, Kumar R, Landberg G 2006 Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients. J Natl Cancer Inst 98:671-680
257. Bostner J, Skoog L, Fornander T, Nordenskjöld B, Stål O 2010 Estrogen receptor-α phosphorylation at serine 305, nuclear p21-activated kinase 1 expression, and response to tamoxifen in postmenopausal breast cancer. Clin Cancer Res 16:1624-1633
258. Goulet I, Gauvin G, Boisvenue S, Côté J 2007 Alternative splicing yields protein arginine methyltransferase 1 isoforms with distinct activity, substrate specificity, and subcellular localization. J Biol Chem 282:33009-33021
259. Fuqua SA, Wiltschke C, Zhang QX, Borg A, Castles CG, Friedrichs WE, Hopp T, Hilsenbeck S, Mohsin S, O'Connell P, Allred DC 2000 A hypersensitive estrogen receptor-α mutation in premalignant breast lesions. Cancer Res 60:4026-4029
260. Conway K, Parrish E, Edmiston SN, Tolbert D, Tse CK, Geradts J, Livasy CA, Singh H, Newman B, Millikan RC 2005 The estrogen receptor-α A908G (K303R) mutation occurs at a low frequency in invasive breast tumors: results from a population-based study. Breast Cancer Res 7:R871-R880
261. Hamilton-Burke W, Coleman L, Cummings M, Green CA, Holliday DL, Horgan K, Maraqa L, Peter MB, Pollock S, Shaaban AM, Smith L, Speirs V 2010 Phosphorylation of estrogen receptor β at serine 105 is associated with good prognosis in breast cancer. Am J Pathol 177:1079-1086
262. He X, Zheng Z, Song T, Wei C, Ma H, Ma Q, Zhang Y, Xu Y, Shi W, Ye Q, Zhong H 2010 c-Abl regulates estrogen receptor α transcription activity through its stabilization by phosphorylation. Oncogene 29:2238-2251
263. Chen D, Riedl T, Washbrook E, Pace PE, Coombes RC, Egly JM, Ali S 2000 Activation of estrogen receptor α by S118 phosphorylation involves a ligand-dependent interaction with TFIIH and participation of CDK7. Mol Cell 6:127-137
264. Weitsman GE, Weebadda W, Ung K, Murphy LC 2009 Reactive oxygen species induce phosphorylation of serine 118 and 167 on estrogen receptor α. Breast Cancer Res Treat 118:269-279
265. Britton DJ, Scott GK, Schilling B, Atsriku C, Held JM, Gibson BW, Benz CC, Baldwin MA 2008 A novel serine phosphorylation site detected in the N-terminal domain of estrogen receptor isolated from human breast cancer cells. J Am Soc Mass Spectrom 19:729-740
266. Park S, Song J, Joe CO, Shin I 2008 Akt stabilizes estrogen receptor α with the concomitant reduction in its transcriptional activity. Cell Signal 20:1368-1374
267. Williams CC, Basu A, El-Gharbawy A, Carrier LM, Smith CL, Rowan BG 2009 Identification of four novel phosphorylation sites in estrogen receptor α: impact on receptor- dependent gene expression and phosphorylation by protein kinase CK2. BMC Biochem 10:36
268. Lee H, Bai W 2002 Regulation of estrogen receptor nuclear export by ligand-induced and p38-mediated receptor phosphorylation. Mol Cell Biol 22:5835-5845
269. Castoria G, Migliaccio A, Green S, Di Domenico M, Chambon P, Auricchio F 1993 Properties of a purified estradiol-dependent calf uterus tyrosine kinase 1. Biochemistry 32:1740-1750
270. Arnold SF, Vorojeikina DP, Notides AC 1995 Phosphorylation of tyrosine 537 on the human estrogen receptor is required for binding to an estrogen response element. J Biol Chem 270:30205-30212
271. Arnold SF, Melamed M, Vorojeikina DP, Notides AC, Sasson S 1997 Estradiol-binding mechanism and binding capacity of the human estrogen receptor is regulated by tyrosine phosphorylation. Mol Endocrinol 11:48-53
272. Márquez DC, Lee J, Lin T, Pietras RJ 2001 Epidermal growth factor receptor and tyrosine phosphorylation of estrogen receptor. Endocrine 16:73-81
273. Urbinati G, Marsaud V, Plassat V, Renoir JM 2011 Nanocarriers targeting breast cancers to deliver modulators of estrogen receptor. In: Souto EB, ed. Lipid nanocarriers in cancer diagnosis and therapy. Akron, Ohio: iSmithers Creative Publishing Solutions 10:279-330